This Fund Built a $26 Million Stake in a Medical Tech Stock That's Soaring After a $9.9 Billion Deal Announcement

Parkman Healthcare Partners initiated a new 200,000-share stake in Masimo (NASDAQ:MASI), with the quarter-end position valued at $26.01M (2.48% of Parkman’s $1.05B U.S. equity assets). Masimo has agreed to be acquired for $180 per share in a transaction valued at roughly $9.9B, shares have rallied ~35% YTD and trade near $175, and the deal is expected to close in H2. The fund’s move indicates timely positioning into a takeover-driven rerating of a company with $1.5B TTM revenue and a ($151.5M) TTM net loss but a $9.4B market cap.

Analysis

The strategic logic behind the recent takeover is not just a one-time premium — it materially alters competitive dynamics in hospital monitoring and workflow automation by accelerating consolidation of point-monitoring, analytics and disposables into a single platform. That consolidation raises the value of recurring consumables and software lock‑in while increasing pressure on smaller standalone device vendors that lack broad OEM/hospital channel reach.

From a catalyst and risk standpoint, this is an event with layered timeframes: an immediate arbitrage window driven by deal close mechanics, a medium-term execution window tied to regulatory/financing and customer contract novations, and a multi‑year value‑realization window for cross‑sell and margin capture. Primary downside triggers are financing stress, a competing bid (which could widen spreads but also delay close), and post‑close integration setbacks that undermine examiner expectations about recurring revenue growth. Litigation or IP disputes remain a latent tail risk given the sector’s history of patent skirmishes.

Second‑order winners include contract manufacturers and consumables suppliers that can scale with a larger platform, and hospital systems that benefit from simplified procurement and total cost of ownership reductions. Second‑order losers are niche monitoring vendors that compete on price rather than integrated workflows; their competitive lifelines will be OEM partnerships or specialization in adjunct niches. The market has bid the target aggressively — the sensible approach is to treat the position as event‑arb exposure with active hedges and to rotate capital into names with clearer recurring revenue optionality.

Key Decisions for Investors

• Event‑arb core: Buy MASI up to a position size of 1.0–2.0% NAV with an immediate protective collar — buy-to-open Jan 2027 put (~10–15% out-of-the-money depending on cost) and sell a nearer-term call to finance the hedge. R/R: limits downside to predefined stress level while capturing convergence to deal consideration over the next 6–12 months; primary risk is deal failure (hedge caps this).
• Pair trade (deal‑risk hedge): Long MASI (0.8% NAV) / Short DXCM (0.8% NAV) for 3–9 months — rationale is asymmetric upside into deal close versus exposure to standalone chronic monitoring re‑rating. R/R: if deal completes MASI re-rates higher; if sector derates both fall, so keep tight stop‑loss and size modest.
• Rotate into recurring revenue winners: Add 0.5–1.0% NAV to SYK or BSX on any MASI‑related sector weakness (6–18 month horizon) — these names benefit from hospital capex normalization and have less binary transaction risk than the target. R/R: lower absolute upside but more stable cashflow exposure if the acquisition stumbles.
• Event failure hedge: If net exposure to the deal exceeds 3% NAV, buy long-dated MASI puts (Jan 2027) equal to that excess or purchase puts on a healthcare equipment ETF to protect against a broader sector unwind. R/R: small insurance premium preserves optionality to re‑establish directional exposure post‑resolution.